Fig. 1From: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?Cumulative proportion of COPD patients receiving “triple therapy” (TT) with LABA + LABA + ICS by GOLD (Global initiative for chronic Obstructive Lung Disease) group, based on a UK primary-care database (2002–2010). Note: P = 0.065 (chi-square test). Elaboration of textual data from [16]Back to article page